Neurobiology of Disease

α -Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β -Spectrin

Gali Maor,¹ Ronald R. Dubreuil,² and Mel B. Feany¹

¹Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115 and ²Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois 60607

 α -Synuclein plays a key role in the pathogenesis of Parkinson's disease and related disorders, but critical interacting partners and molecular mechanisms mediating neurotoxicity are incompletely understood. We show that α -synuclein binds directly to β -spectrin. Using males and females in a *Drosophila* model of α -synuclein-related disorders, we demonstrate that β -spectrin is critical for α -synuclein neurotoxicity. Further, the ankyrin binding domain of β -spectrin is required for α -synuclein binding and neurotoxicity. A key plasma membrane target of ankyrin, Na⁺/K⁺ ATPase, is mislocalized when human α -synuclein is expressed in *Drosophila*. Accordingly, membrane potential is depolarized in α -synuclein transgenic fly brains. We examine the same pathway in human neurons and find that Parkinson's disease patient-derived neurons with a triplication of the α -synuclein locus show disruption of the spectrin cytoskeleton, mislocalization of ankyrin and Na⁺/K⁺ ATPase, and membrane potential depolarization. Our findings define a specific molecular mechanism by which elevated levels of α -synuclein in Parkinson's disease and related α -synucleinopathies lead to neuronal dysfunction and death.

Key words: a-synuclein; Drosophila; Parkinson's disease; spectrin

Significance Statement

The small synaptic vesicle associate protein α -synuclein plays a critical role in the pathogenesis of Parkinson's disease and related disorders, but the disease-relevant binding partners of α -synuclein and proximate pathways critical for neurotoxicity require further definition. We show that α -synuclein binds directly to β -spectrin, a key cytoskeletal protein required for localization of plasma membrane proteins and maintenance of neuronal viability. Binding of α -synuclein to β -spectrin alters the organization of the spectrin-ankyrin complex, which is critical for localization and function of integral membrane proteins, including Na⁺/K⁺ ATPase. These finding outline a previously undescribed mechanism of α -synuclein neurotoxicity and thus suggest potential new therapeutic approaches in Parkinson's disease and related disorders.

Introduction

Parkinson's disease is the most common neurodegenerative movement disorder, affecting 1% of individuals at age 65 (Van Den Eeden et al., 2003; de Lau and Breteler, 2006; Yang et al., 2019). There are currently no effective disease-modifying therapies for Parkinson's disease and related disorders, emphasizing the importance of delineating the underlying pathobiology so

Received Oct. 11, 2022; revised Nov. 30, 2022; accepted Dec. 8, 2022.

The authors declare no competing financial interests.

Correspondence should be addressed to Mel B. Feany at mel_feany@hms.harvard.edu.

https://doi.org/10.1523/JNEUROSCI.1922-22.2022

```
Copyright © 2023 the authors
```

that rational therapeutics can be developed. Genetics and neuropathology have converged to implicate strongly the small, 140 amino acid, protein α -synuclein in the pathogenesis of Parkinson's disease and related diseases. Point mutations, duplications, and triplications of the α -synuclein locus cause autosomal dominant, highly penetrant familial forms of Parkinson's disease (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz et al., 2004; Book et al., 2018). In both rare forms of genetic Parkinson's disease linked to α -synuclein mutations and in more common forms of the disorder, α -synuclein is deposited into a variety of intracellular protein aggregates. Aggregation of α -synuclein is also seen in the related neurodegenerative disorders dementia with Lewy bodies and multiple system atrophy. These diseases are collectively termed α -synucleinopathies.

The implication of elevated α -synuclein levels as a cause of Parkinson's disease has led to the development of animal models based on increased expression of human α -synuclein. In monkeys, rats, mice, fish, flies, and worms, expression of human α -synuclein can mimic key features of Parkinson's disease, including progressive locomotor dysfunction, degeneration of dopaminergic and

Author contributions: G.M., R.R.D., and M.B.F. designed research; G.M., R.R.D., and M.B.F. performed research; G.M., R.R.D., and M.B.F. wrote the paper.

This work was supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke R01NS098821 and ASAP-000301. Fly stocks were obtained from the Bloomington Drosophila Stock Center (National Institutes of Health P400D018537) and Christopher Potter. Monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by the University of Iowa, Department of Biology, and the University of California–Davis/National Institutes of Health NeuroMab Facility. We thank Dr. Matthew Rasband for kindly providing the β IV-spectrin antibody.



Figure 1. Elevated expression of β -spectrin rescues α -synuclein neurotoxicity. *A*, Climbing activity in control and human α -synuclein transgenic *Drosophila* with and without elevated expression of β -spectrin. n = minimum of 60 flies per genotype (six biological replicates of 10 flies each). *B*, *C*, Brain degeneration assayed by hematoxylin staining in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without elevated expression of β -spectrin; n = 6. *D*, *E*, Immunostaining for TH in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without elevated expression of β -spectrin; n = 6. *D*, *E*, Immunostaining for TH in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without elevated expression of β -spectrin. n = 6. *F*, *G*, The normal spectrin subplasmalemmal network is disrupted by expression of human α -synuclein. Arrows indicate disruptions in the spectrin network. n = 6. All flies are 10 d old. Controls are *nSyb-QF2*, *nSyb-GAL4/+*. Scale bars: *B*, 10 µm; *D*, *F*, 5 µm. Data are mean \pm SEM. *p* values determined with one-way ANOVA with Bonferroni *post hoc* test (see Extended Data Fig. 1-1).

nondopaminergic neurons, and α -synuclein aggregation (Feany and Bender, 2000; Masliah et al., 2000; Kirik et al., 2002, 2003; M. K. Lee et al., 2002; Lakso et al., 2003; O'Donnell et al., 2014). Since flies and worms do not normally express α -synuclein, toxicity plausibly represents gain of function of the human protein. Using these animal α -synucleinopathy models, a variety of processes, including phosphorylation and aggregation of α -synuclein (Chen and Feany, 2005; Lo Bianco et al., 2008; Chen et al., 2009; Kuwahara et al., 2012), mitochondrial dysfunction (Martin et al., 2006; Ordonez et al., 2018; Sarkar et al., 2020; Portz and Lee, 2021), and altered proteostasis (Auluck et al., 2002; Colla et al., 2012; Yan et al., 2019; Karim et al., 2020; Sarkar et al., 2021), have been implicated in α -synuclein neurotoxicity. However, the proximal mechanisms linking α -synuclein to downstream mediators have remained unclear. We now show that α -synuclein binds directly to β -spectrin *in vitro* and mediates neurotoxicity *in vivo* by disrupting ankyrin- and spectrin-dependent localization and function of the plasma membrane Na⁺/K⁺ ATPase.



Figure 2. Reduced expression of β -spectrin enhances α -synuclein neurotoxicity. **A**, Climbing activity in control and α -synuclein transgenic *Drosophila* with and without reduced expression of β -spectrin. n = minimum of 60 flies per genotype (six biological replicates of 10 flies each). **B**, **C**, Brain degeneration assayed by hematoxylin staining in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without reduced expression of β -spectrin; n = 6. **D**, **E**, Immunostaining for TH in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without expression of β -spectrin, n = 6. All flies are 10 d old. β -spectrin^{KD} flies are hemizygous for the complete loss-of-function mutation β -spec^{em21}, rescued to viability with transgenic expression of the β -spec^{t/pn+3} variant, which accumulates at significantly reduced levels. Controls are *nSyb-QF2*, *nSyb-GAL4/+*. Scale bars: **B**, 10 µm; **D**, 5 µm. Data are mean \pm SEM. *p* values determined with one-way ANOVA with Bonferroni *post hoc* test (see Extended Data Fig. 1-1).

Materials and Methods

Drosophila stocks and genetics. All fly crosses and aging were performed at 25°C. Equal numbers of adult male and female flies were analyzed at 10 d after eclosion, except as otherwise indicated in the figure legends. The QUAS- α -synuclein WT transgenic flies have been reported previously (Ordonez et al., 2018). N-terminally myc-tagged β -spectrin WT (β -spectrin^{KW3A}), β -spectrin^{Δ ank} (β -spectrin^{α 13}), and β -spectrin^{Δ PH} transgenes were expressed under the control of the Drosophila ubiquitin promotor. These β -spectrin transgenic flies have been described in detail previously (Das et al., 2006). Expression of α -synuclein was directed to neurons using the pan-neuronal driver *nSyb-QF2*. GAL4-mediated expression was controlled by the pan-neuronal *nSyb-GAL4* driver, from the Bloomington Drosophila Stock Center. The *nSyb-QF2* line was obtained from C. Potter.

Behavioral analysis. The climbing assay was performed as described in detail previously (Ordonez et al., 2018). Briefly, 10 flies were placed in individual vials and a total of six vials assayed per genotype, for a total of 60 flies per genotype. Flies were tapped down gently to the bottom of the vial, and the number of flies climbing above 5 cm within 10 s was recorded. Results are reported as the mean \pm SEM.

Induced pluripotent stem cells (iPSCs) and neuronal differentiation. NGN2-iPSCs from a female donor were obtained from Brigham and Women's iPSC Neurohub and maintained as feeder-free cells in a defined, serum-free media (mTeSR, STEMCELL Technologies). For neuronal induction, cells were dissociated with Accutase (STEMCELL Technologies) and plated in mTeSR supplemented with 10 μ M ROCK inhibitor Y-27632 and 2 μ g/ml doxycycline on a Matrigel-coated 6-well plate. On day 1 of the differentiation, culture media was changed to DMEM/F12 supplemented with N2 (Invitrogen), B27 (Invitrogen),

nonessential amino acids, GlutaMAX, 5 µg/ml puromycin, and 2 µg/ml doxycycline. On day 4 of differentiation, media was changed to Neurobasal media (Invitrogen) supplemented with B27 (Invitrogen), 10 ng/µl BDNF, CNTF and GDNF, 10 µM ROCKi, 5 µg/ml puromycin, and 2 µg/ml doxycycline. Medium was changed every 3 d. For the imaging studies reported, at least three independent differentiations of triplication and isogenic control neurons plated in parallel were performed and analyzed.

Histology, immunohistochemistry, and immunofluorescence. For examination of the adult fly brain, animals were fixed in formalin and embedded in paraffin; $4\,\mu$ m serial frontal sections were prepared through the entire brain and placed on a single glass slide. Hematoxylin staining was performed on paraffin sections to assess total neuronal density. Neurons differentiated from iPSCs were fixed in 4% PFA before proceeding to immunostaining.

For immunostaining of paraffin sections, slides were processed through xylene, ethanol, and into water. Antigen retrieval by boiling in sodium citrate, pH 6.0, was performed before blocking. In some studies, whole-mount *Drosophila* brain preparations were alternatively used. Blocking was performed in PBS containing 0.3% Triton X-100 and 2% milk for 1 h and followed by incubation with appropriate primary antibodies overnight. Primary antibodies used were as follows: anti-TH (Immunostar) at 1:500; anti- α -synuclein (5G4, Millipore) at 1:1000,000; anti- β -spectrin (R.R.D. laboratory) at 1:1000; antinrv1 (Nrv5F7, Developmental Studies Hybridoma Bank) at 1:100; anti-ankyrin/ankyrin B (N105/17, NeuroMab) at 1:200; anti- β II-spectrin (BD Biosciences) at 1:500; anti-ATP1B1 (Abcam); anti- β IV-spectrin (polyclonal antibody from M. Rasband) at 1:500; anti-ankyrin G (N106/36, NeuroMab) at 1:200; anti-tubulin β 3 (Biolegend) at 1:500; and anti-MAP2 (Abcam) at 1:500. For immunohistochemistry, biotin-



Figure 3. α -Synuclein interacts directly with β -spectrin, but not α -spectrin. **A**, Human α -synuclein and *Drosophila* β -spectrin interact in Ni-NTA and GST pull-down assays as monitored by immunoblotting for β -spectrin (His) or α -synuclein. **B**, No interaction of human α -synuclein and *Drosophila* α -spectrin in Ni-NTA or GST pull-down assays as monitored by immunoblotting for β -spectrin (His) or α -synuclein and human β II-spectrin interact in Ni-NTA and GST pull-down assays as monitored by immunoblotting for β -spectrin (His) or α -synuclein and human β II-spectrin interact in Ni-NTA and GST pull-down assays as monitored by immunoblotting for β I-spectrin (His) or α -synuclein. **D**, No interaction of human α -synuclein and human α II-spectrin in Ni-NTA or GST pull-down assays as monitored by immunoblotting for α -synuclein. **E**, Immunoprecipitation of α -synuclein in control and α -synuclein transgenic flies shows an association between α -synuclein and β -spectrin. Flies are 10 d old.

conjugated secondary antibodies (1:200, Southern Biotechnology) and avidin-biotin-peroxidase complex (Vectastain Elite, Vector Laboratories) staining was performed using DAB (Vector Laboratories) as a chromagen. For immunofluorescence studies, appropriate AlexaFluor-conjugated secondary antibodies (Alexa-488, Alexa-555, or Alexa-647, 1:200, Invitrogen) were used.

For quantification of TH-positive neurons and aggregated α -synuclein in *Drosophila* brains, an entire tissue cross section of the anterior medulla was imaged. One image per fly and a total of 6 flies per genotype were used for quantification. The number of TH-positive cells detected by immunohistochemistry or α -synuclein aggregates detected with immunofluorescence in each image was counted and results were expressed per unit area.

Cloning, protein purification, and precipitation. WT Drosophila and human spectrins were cloned into a histidine-tagged vector (2BC-T cloning vector, Addgene #31070) using ligation-independent cloning to obtain C-terminally tagged proteins. Briefly, the vector was linearized using HpaI digestion. Inserts encoding fly and human α - and β -spectrins were PCR-amplified using appropriate primers. Following amplification, constructs were annealed at room temperature for 5 min. Mutant Drosophila and human β -spectrins (β -spec^{Δ ank}) were produced by VectorBuilder (https://en.vectorbuilder.com/). In both mutants, the sequence of the 15th β -spectrin repeat was replaced with the sequence of the 12th α -spectrin repeat, as in the β -spec^{Δ ank} transgenic flies (Das et al., 2006).

For isolation of recombinant protein, overnight cultures of transformed BL21 cells were induced with 1 mM Isopropyl-b-D-1-thiogalactopyranoside at 37°C for 4 h and harvested by centrifugation. Proteins were eluted using Ni-NTA spin columns according to the manufacturer's protocol (QIAGEN). Glutathione-S-transferase- α (GST- α) synuclein fusion protein tagged at the N-terminus was obtained from Sigma Aldrich; 200 µg of GST- α synuclein was incubated with the equivalent amount of purified His-spectrin at 4°C overnight in the presence of glutathione Sepharose beads. The pull-downs were washed 4 times with lysis buffer and finally resolved by boiling in $2 \times$ Laemmli sample buffer (63 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.0025% bromophenol blue) at 95°C for 5 min; 200 µg of the proteins was incubated with equivalent amount of GST- α synuclein fusion protein at 4°C overnight in the presence of Ni-NTA beads (Invitrogen). The pull-downs were washed 4 times with lysis buffer and boiled in $2\times$ Laemmli sample buffer for 5 min.

Immunoprecipitation. To assess α -synuclein and β -spectrin interaction *in vivo*, immunoprecipitation was performed. Ten fly heads or differentiated neurons from a confluent 10 cm culture plate were homogenized in nondenaturing lysis buffer (20 mM Tris–HCl, pH 8, 137 mM NaCl, 1% Triton X-100, 2 mM EDTA) and centrifuged at



Figure 4. The ankyrin binding domain of β -spectrin mediates interactions with α -synuclein. **A**, Schematic diagram of the domains of WT β -spectrin and the two mutant versions of spectrin used (β -spec^{Δ ank} and β -spec^{Δ ank} and β -spec^{Δ ank} in the domain α -synuclein transgenic *Drosophila* with and without elevated expression of WT and mutant forms of β -spectrin. n = minimum of 60 flies per genotype (six biological replicates of 10 flies each). **C**, **D**, Brain degeneration assayed by hematoxylin staining in the anterior medulla of control and

12,000 rpm to pellet debris. The supernatant was incubated with the H3C monoclonal α -synuclein antibody with rotation for 12 h at 4°C. Protein-G Sepharose beads (GE Healthcare) were blocked in 0.1% BSA for 1 h at room temperature, washed, and added to cell lysates for incubation with rotation for 4 h at 4°C. The precipitated material was then washed 4 times in lysis buffer, resuspended with SDS loading buffer, and subjected to immunoblotting.

Western blots. Drosophila heads were homogenized in $2\times$ Laemmli sample buffer. All samples were boiled for 10 min, briefly centrifuged, and subjected to SDS-PAGE using 10% gels (Bio-Rad). Proteins were transferred to nitrocellulose membranes (Bio-Rad), blocked in 2% milk in PBS with 0.05% Tween-20, and immunoblotted with primary antibodies. Primary antibodies used were anti- α -synuclein (H3C, Developmental Studies Hybridoma Bank) at 1:500,000, anti-c-Myc (9E10, Developmental Studies Hybridoma Bank) at 1:1000, anti-6XHis (N144/14, NeuroMab) at 1:500, and anti-GAPDH (Invitrogen) at 1:1000. The appropriate IRDye fluorescence secondary antibody (1:10,000, LICOR) was applied. Images were taken using a LICOR Odyssey DLx imaging system (LICOR). Blots were repeated at least 3 times, and a representative blot shown.

Fluorescence microscopy. Confocal images were taken on a Zeiss LSM-800 confocal microscope with Airyscan. For the evaluation of β IIspectrin cytoskeleton, the axon initial segment, and ankyrin-B and Na⁺/ K⁺ ATPase localization in neurons differentiated from iPSC three independent differentiations of triplication and isogenic control neurons plated in parallel were performed. For each parallel set of isogenic control and triplication neurons, three coverslips were analyzed with a total of ~ 1000 neurons analyzed for each control and triplication cells. Imaged regions were selected based on optimal cell density to allow visualization of the soma, axon, and dendrites of individual neurons, and on consistent immunostaining. All cells within an imaged field were analyzed and (1) the percentage of cells with disrupted β II-spectrin cytoskeleton, (2) the staining pattern of ankyrin-G and β IV-spectrin, and (3) localization of ankyrin-B and Na⁺/K⁺ ATPase was assessed. For quantification of ankyrin-B and Na⁺/K⁺ ATPase localization, the fluorescence intensity of staining in the plasma membrane as well as in the cytoplasm was measured in the soma. Plasma membrane staining was derived by subtraction of the cytoplasmic staining from total staining of the cells.

Plasma membrane polarization. The voltage-sensitive fluorescent dye bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBAC₄(3)) was used in Drosophila brains and cultured neurons. Relative fluorescent intensities were recorded; higher intensities indicated depolarization of the plasma membrane. Brains from 10-d-old flies were dissected in Schneider's media and incubated with 4 μ M DiBAC₄(3) for 20 min at 25°C. Brains were then mounted and confocal microscopy performed immediately with quantification of average pixel intensity from two-dimensional projections of confocal z stacks representing the entire brain using ImageJ. Imaging and analysis for all genotypes were done at the same confocal settings, including laser intensity and z-stack thickness. Results represent the average of 6 flies per genotype. Cultured cells were incubated in 200 nm DiBAC₄(3) in DMEM/F12 for 20 min in 37°C incubator at 21 DIV. Cells were imaged without washing. Results represent an average of 100 cells per cell line. Imaging and analysis for both cell lines were done at the same confocal settings.

←

Stimulated emission depletion (STED) microscopy. To analyze the spectrin cytoskeleton and cellular localization of ankyrin and Na⁺/K⁺ ATPase, Drosophila brains from 10-d-old flies were dissected and fluorescently labeled using standard protocols and mounted using Prolong Diamond antifade mounting medium (Invitrogen). Imaging of Kenyon cells was performed using a STED instrument mounted on a Leica SP8 confocal microscope. Fluorophores were excited at 488 or 550 nm from a white light laser, and depletion of the signal was done at 592 and 660 nm, respectively. A time gate was used to reject photons with a lifetime outside a 1.3 and 6 ns time window. To achieve optimal resolution, pixel size was matched to be 25 nm, with averaging of four images. For quantification of spectrin cytoskeletal disruption and membrane and cytosolic ankyrin and Na⁺/K⁺ ATPase, a well-stained optical section from the midportion of the mushroom body Kenyon cell layer representing the entire thickness of the cortex and including \sim 30 cells was imaged. To quantify spectrin cytoskeletal disruption the number of cells with focal or multifocal discontinuities of the subplasmalemmal spectrin network was counted in each image. For analysis of ankyrin and Na⁺/ K⁺ ATPase, the intensity from each cell in the image was measured. A total of 6 animals per genotype were assessed. For colocalization studies, the Pearson coefficient was calculated from four images per animal, each image containing 20 cells.

Statistical analysis. Nonparametric statistical tests were used for all comparisons. Details regarding statistical tests, biological sample size (*n*) and *p* value are present in the figure legends. All data are represented as mean \pm SEM; SEM represents variance within a group. Data were collected and processed side by side in randomized order for all experiments. Unpaired, two-tailed *t* tests were used for comparison between two groups, with *p* < 0.05 considered significant. For all comparisons involving multiple variables, one-way or two-way ANOVA was performed followed by Bonferroni tests for multiple comparison using *p* < 0.05 for significance. All statistical analyses were preformed using GraphPad Prism.

Results

We have previously described a Drosophila model of Parkinson's disease and related α -synucleinopathies based on expression of WT human α -synuclein in a pan-neuronal pattern. Our model recapitulates key features of the human disorder, including progressive locomotor dysfunction, age-dependent neurodegeneration, and α -synuclein aggregation (Feany and Bender, 2000; Ordonez et al., 2018). In prior work, we further observed that α -synuclein neurotoxicity depended on the levels of α -spectrin (Ordonez et al., 2018). Spectrins are highly conserved tetrameric cytoskeletal proteins consisting of two α and two β subunits. Drosophila is a favorable model system for the study of spectrin function because spectrins are encoded by just three genes in flies: one α -spectrin gene, one β -spectrin gene, and one β_{H} -spectrin gene. We previously found that increased expression of α -spectrin could rescue downstream toxicity of α -synuclein, including mitochondrial dysfunction and neuronal death (Ordonez et al., 2018). However, other studies have suggested that β -spectrin, as well as α -spectrin, can interact with α -synuclein (Leverenz et al., 2007; McFarland et al., 2008; H. J. Lee et al., 2012; Chung et al., 2017). We therefore expressed β -spectrin together with α -synuclein in our fly model to determine whether β -spectrin can modulate α -synuclein neurotoxicity in vivo. We found, as reported previously, that α -synuclein transgenic flies displayed impaired locomotor function as assessed by the climbing assay. Elevated expression of transgenic β -spectrin ameliorated locomotor dysfunction in α -synuclein transgenic flies (Fig. 1A). Similarly, degeneration as assessed by total numbers of cortical cells (Fig. 1B,C) and numbers of TH-positive dopamine neurons (Fig. 1D, arrows, Fig. 1E) was also rescued by elevated expression of β -spectrin.

 $[\]alpha$ -synuclein transgenic *Drosophila* with and without elevated expression WT and mutant forms of β -spectrin. n = 6. **E**, **F**, Immunostaining for TH in the anterior medulla of control and α -synuclein transgenic *Drosophila* with and without elevated expression WT and mutant forms of β -spectrin. n = 6. **G**, **H**, Human α -synuclein and WT *Drosophila* β -spectrin, but not β -spec^{Δ ank}, interact in GST (**G**) or Ni-NTA (**H**) pull-down assays as monitored by immunoblotting for β -spectrin (His) or α -synuclein. **I**, **J**, Human α -synuclein and WT β II-spectrin, but not β II-spec^{Δ ank}, interact in GST (**I**) or Ni-NTA (**J**) pull-down assays as monitored by immunoblotting for β -spectrin (His) or α -synuclein. All flies are 10 d old. Control flies are *nSyb-QF2*, *nSyb-GAL4/+*. Scale bars: **A**, 5 µm; **C**, 10 µm. Data are mean ± SEM. *p* values determined with one-way ANOVA with Bonferroni *post hoc* test.



Figure 5. Expression of α -synuclein leads to mislocalization of ankyrin and Na⁺/K⁺ ATPase in *Drosophila* neurons. *A*, *B*, STED microscopy reveals colocalization of ankyrin (red) with subplasmalemmal β -spectrin (green) in WT animals and increased cytoplasmic ankyrin (arrows) with expression of human α -synuclein. Elevated expression of β -spectrin partially normalizes ankyrin localization. *n* = 6. *C*, Pearson's correlation coefficient reveals an infrequent association between β -spectrin and ankyrin in α -synuclein transgenic *Drosophila*. Association is partially restored with elevated expression of β -spectrin. *D*, *E*, STED microscopy reveals substantial colocalization of Na⁺/K⁺ ATPase (red) with β -spectrin (green) in WT animals and increased

Rescue did not simply reflect reduced levels of α -synuclein since Western blotting revealed equivalent levels of α -synuclein when β -spectrin was increased in expression (Extended Data Fig. 1-1*A*,*B*).

The spectrin cytoskeleton is anchored to the cytoplasmic face of the plasma membrane and is believed to form a network that contributes to maintaining the structure and shape of the cell (Dubreuil, 2006; Morrow and Stankewich, 2021; Teliska and Rasband, 2021). Immunostaining revealed regular subplasmalemmal β -spectrin staining in the brains of control flies (Fig. 1F) (Das et al., 2008). In contrast, staining was irregular and disrupted in the brains of α -synuclein transgenic flies (Fig. 1F, arrows, Fig. 1G), similar to the pattern seen with perturbed β -spectrin function (Das et al., 2008). Elevated expression of β -spectrin partially restored the β -spectrin staining pattern in flies expressing α -synuclein (Fig. 1F,G).

We next examined the functional consequences of lowering levels of β -spectrin in α -synuclein transgenic flies. Animals with no β -spectrin die as late embryos or early larvae (Dubreuil et al., 2000; Das et al., 2006). We therefore used flies with a complete loss of function β -spectrin mutation (β -spec^{em21}) combined with a transgene expressing an engineered mutant of β -spectrin with three amino acid substitutions in the actin binding domain $(\beta$ -spectrin^{Kpn+3}) (R.R.D., unpublished observations), which accumulates at significantly reduced levels (Extended Data Fig. 1-1) but rescues lethality of β -spectrin loss of function. We therefore used hemizygous male β -spec^{em21} flies rescued to adulthood by one copy of the β -spectrin^{Kpn+3} transgene in our β -spectrin knockdown experiments, termed β -spectrin^{KD} here for simplicity (Fig. 2). α -Synuclein transgenic flies with loss of β -spectrin function exhibited a significant enhancement of locomotor dysfunction (Fig. 2A). Similarly, degeneration, as monitored by total numbers of cortical cells (Fig. 2B,C) or TH-positive neurons (Fig. 2D, arrows, Fig. 2E), worsened with reduced β -spectrin expression.

To determine whether α -synuclein interacts directly with spectrin, we expressed histidine-tagged α and β -spectrin proteins in bacteria. Each spectrin was purified, incubated with purified, GST-tagged human α -synuclein, and the samples precipitated with Ni-NTA or glutathione Sepharose beads. *Drosophila* β -spectrin bound to α -synuclein *in vitro* (Fig. 3A), which we verified *in vivo* by immunoprecipitation (Fig. 3E). We also determined that human β II-spectrin (Fig. 3C) bound to α -synuclein *in vitro*, as seen by both GST and Ni-NTA precipitation. We began by assessing human β II-spectrin because of the five mammalian β -spectrins, β I, β II, β III, β IV, and β V (Lorenzo, 2020). The β II isoform is abundant in the nervous system and is most similar to the conventional *Drosophila* β -spectrin. In contrast to the β -spectrins, interactions between Drosophila α -spectrin or human α II-spectrin and α -synuclein were not detected *in vitro* (Fig. 3*B*,*D*). Of the two mammalian α -spectrins, α II-spectrin is expressed in brain, while α I-spectrin is predominantly found in red blood cells (Lorenzo, 2020).

 β -Spectrin is a modular protein with multiple domains mediating interactions with specific partners in the cell (Fig. 4A). We have previously described β -spectrin transgenic flies expressing β -spectrin lacking ankyrin-binding activity (β -spec^{Δ ank}) or β -spectrin with deletion of the pleckstrin homology (PH) domain (β -spec^{Δ PH}) at levels similar to the endogenous protein and with similar levels of mutant compared with WT transgenic β -spectrin (Fig. 4A; Extended Data Fig. 1-1) (Das et al., 2006). In the case of β -spec^{ΔPH}, a nonsense mutation was introduced immediately upstream of the PH domain, resulting in expression of a slightly truncated protein. In β -spec^{Δ ank}, an entire spectrin repeat (repeat 15) containing the ankyrin binding site was excised from β -spectrin and replaced with a repeat from α -spectrin (repeat 12) that preserves the structure of β -spectrin, but removes ankyrin binding activity. Expression of β -spec^{Δ PH} rescued locomotor deficits (Fig. 4*B*) and neurodegeneration (Fig. 4C-F) in α -synuclein transgenic flies. In contrast, expression of β -spec^{Δ ank} did not rescue locomotor defects (Fig. 4B) or neurodegeneration (Fig. 4C-F), implicating ankyrin binding in α -synuclein neurotoxicity.

We next purified bacterially expressed, histidine-tagged β -spec^{Δ ank}, and assessed binding to GST-tagged human α -synuclein. In contrast to WT β -spectrin, β -spec^{Δ ank} failed to associate with α -synuclein as assayed by either GST (Fig. 4G) or Ni-NTA precipitation (Fig. 4H). We created a mutant in human β II-spectrin similar to fly β -spec^{Δ ank} by replacing the human β II-spectrin repeat 15 with the human α -spectrin repeat 12. We expressed the histidine-tagged mutant human protein in bacteria, purified the protein, and assessed binding to GST-tagged human α -synuclein. As observed with the *Drosophila* β -spec^{Δ ank} protein, the human β II-spectrin repeat 15 with the *Drosophila* β -spec^{Δ ank} protein, the human β II-spectrin repeat 15 is critical for binding of α -synuclein to β -spectrin repeat 15 is critical for binding of α -synuclein to β -spectrin as well as for neurotoxicity (Fig. 4B-F).

Spectrin is present at the inner surface of the plasma membrane in a complex, including ankyrin, the Na⁺/K⁺ ATPase, and cell adhesion molecules (Das et al., 2006; Dubreuil, 2006; Mazock et al., 2010; Morrow and Stankewich, 2021; Teliska and Rasband, 2021). We examined the localization of ankyrin and Na⁺/K⁺ ATPase in α -synuclein transgenic flies by STED microscopy following immunostaining of whole-mount brains. In control flies, the pattern of ankyrin overlapped that of β -spectrin, both localizing near the plasma membrane (Fig. 5A-C). The distribution of ankyrin was significantly altered in the α -synuclein transgenic flies, with an increase in cytosolic staining (Fig. 5A,B). Elevated expression of β -spectrin significantly restored the WT distribution of ankyrin (Fig. 5A–C). Similarly, Na^+/K^+ ATPase redistributed to the cytoplasm from the plasma membrane on expression of human α -synuclein in transgenic flies as monitored by immunostaining with the monoclonal antibody Nrv5F7, which recognizes the β subunit of the enzyme (Sun and Salvaterra, 1995). Expression of β -spectrin normalized the distribution of Na^+/K^+ ATPase (Fig. 5D-F).

 Na^+/K^+ ATPase plays a critical role in maintaining the ion gradients between the extracellular and intracellular environments, which in turn controls the resting membrane potential (Clausen et al., 2017). We assessed the effect of α -synuclein expression on membrane potential in flies by incubating dissected

cytoplasmic Na⁺/K⁺ ATPase (arrows) with expression of human α -synuclein. Elevated expression of β -spectrin partially normalizes Na⁺/K⁺ ATPase localization. n = 6. **F**, Pearson's correlation coefficient reveals an infrequent association between β -spectrin and Na⁺/K⁺ ATPase in α -synuclein transgenic *Drosophila*. Association is partially restored with elevated expression of β -spectrin. **G**, **H**, Loss of plasma membrane polarization as monitored by DiBAC₄(3) following expression of human α -synuclein. Elevated expression of β -spectrin partially normalizes membrane polarization. n = 6. **I**, **J**, Immunofluorescence microscopy (*I*) and quantification (*J*) showing increased numbers of α -synuclein aggregates in neurons from fly brain sections of α -synuclein transgenic *Drosophila* with elevated β -spectrin. n = 6. All flies are 10 d old. Controls are *nSyb*, *nSyb-GAL4/+*. Scale bars: **A**, **C**, 2 µm; **I**, 5 µm; **E**, 50 µm. Data are mean \pm SEM. *p* values determined with one-way ANOVA with Bonferroni *post hoc* test.



Figure 6. Increased expression of α -synuclein leads to disruption of the spectrin cytoskeleton and mislocalization of ankyrin and Na⁺/K⁺ ATPase in human neurons. *A*, *B*, The normal β II-spectrin immunoreactive subplasmalemmal network (red) is disrupted by increased expression of human α -synuclein in MAP2-positive (green) α -synuclein triplication patient neurons compared with isogenic control neurons. Arrows indicate cells with reduced β II-spectrin staining. n = 9. *C*, Immunoprecipitation of α -synuclein in control and α -synuclein triplication patient-

brains with the voltage-sensitive fluorescent dye DiBAC₄(3) (Bhavsar et al., 2019; Weiß and Bohrmann, 2019). α -Synuclein transgenic flies showed significant depolarization in whole dissected brains compared with control flies, demonstrated as increased fluorescent intensity (Fig. 5*G*,*H*). Elevated expression of β -spectrin partially normalized membrane potential in whole-mount brains from α -synuclein transgenic flies (Fig. 5*G*,*H*).

Aggregation of α -synuclein has been linked to neurotoxicity (Chen and Feany, 2005; Periquet et al., 2007; Lo Bianco et al., 2008; Shulman et al., 2011; Burré et al., 2018). We therefore assessed the number of aggregates present in α -synuclein transgenic flies with elevated levels of β -spectrin. We found increased numbers of inclusions in β -spectrin transgenic flies (Fig. 5*I*,*J*), consistent with our prior findings in α -spectrin transgenic animals (Ordonez et al., 2018).

To determine whether results in the Drosophila α -synucleinopathy model extended to human cells, we used neurons differentiated from patient-derived iPSCs with a triplication of the α -synuclein locus and isogenic control cells (Devine et al., 2011; Ho et al., 2021). Immunostaining for β II-spectrin revealed the characteristic subplasmalemmal staining pattern in control neurons (Fig. 6A). In contrast, β II-spectrin immunostaining did not consistently show subplasmalemmal distribution in triplication neurons (Fig. 6A, arrows, Fig. 6B). We confirmed that human β II-spectrin communoprecipitated with α -synuclein in homogenates from human neurons (Fig. 6C). We next examined ankyrin in human neurons. There are three mammalian ankyrin isoforms: ankryin-B, ankyrin-R, and ankyrin-G. Ankryin-B is expressed in a widespread pattern in the nervous system, while ankyrin-R and ankyrin-G have more specific cellular and subcellular localization (Kordeli and Bennett, 1991; Lorenzo, 2020). When we stained for ankryin-B, we observed increased cytoplasmic staining compared with isogenic controls (Fig. 6D, arrows, Fig. 6*E*), similar to findings in α -synucleinopathy model fly brains (Fig. 5A,B). We next used an antibody recognizing the β I subunit of human Na⁺/K⁺ ATPase to examine localization of Na⁺/K⁺ ATPase. As in α -synuclein transgenic Drosophila brains (Fig. 5D,E), we found increased cytosolic staining for human Na^+/K^+ ATPase in α -synuclein triplication neurons (Fig. 6*F*, arrows, Fig. 6*G*). Alteration of Na^+/K^+ ATPase localization was accompanied by plasma membrane depolarization as monitored by DiBAC₄(3) fluorescence in human triplication neurons compared with isogenic controls (Fig. 6H).

In addition to anchoring plasma membrane proteins, such as Na^+/K^+ ATPase, ankyrins also organize discrete membrane domains of neurons. In particular, ankyrin-G localizes to and

organizes the axon initial segment (Leterrier, 2018). We thus examined the axon initial segment in triplication and control neurons. Immunofluorescence using an antibody to ankyrin-G identified a well-defined axon initial segment in most control neurons (Fig. 6*I*, arrows, Fig. 6*K*). In contrast, many triplication neurons displayed patchy staining for ankyrin-G, a pattern consistent with a fragmented axon initial segment (Galiano et al., 2012; Torii et al., 2020) (Fig. 6*I*, insets, arrowheads, Fig. 6*K*). We confirmed our findings with a second marker of the axon initial segment, β IV-spectrin. Similar to ankyrin-G, immunostaining for β IV-spectrin revealed decreased numbers of intact axon initial segments in triplication neurons (Fig. 6*J*, arrows, Fig. 6*L*), with fragmentation of many axon initial segments (Fig. 6*J*, insets, arrowheads, Fig. 6*L*).

Discussion

Here we demonstrate that pathologic expression of α -synuclein in fly or human neurons leads to disruption of the subplasmalemmal spectrin network, mislocalization of ankyrins and Na⁺/ K⁺ ATPase, consequent dysregulation of neuronal membrane potential, and ultimately neurodegeneration. Our biochemical results suggest that disruption of the spectrin network reflects direct binding of α -synuclein to β -spectrin (Fig. 3). These findings are consistent with prior studies showing that α -synuclein colocalizes with β -spectrin in Lewy bodies from brains of patients with Lewy bodies (Leverenz et al., 2007). Intriguingly, β -spectrin has been linked genetically to the α -synucleinopathy dementia with Lewy bodies through genome association studies (Peuralinna et al., 2015). More generally, human genetic and animal model studies have demonstrated a critical role for spectrins in the development and function of the nervous system (Morrow and Stankewich, 2021). Mutations in the genes encoding spectin isoforms give rise to neurodegenerative ataxias (β III-spectrin), neurodevelopmental and behavioral deficits (β II and β III-spectrin), and deafness (β IV- and β V-spectrin) (Cousin et al., 2021; Morrow and Stankewich, 2021; Teliska and Rasband, 2021). Our current results suggest that the α -synucleinopathies may represent additional members of the human spectrinopathy family of neurologic diseases.

Experiments in animal and cell culture models of α -synucleinopathy have implicated alterations in multiple fundamental cellular processes, including vesicular trafficking (Chung et al., 2013; Burré et al., 2018; Vidyadhara et al., 2019), mitochondrial dynamics and function (Martin et al., 2006; Ordonez et al., 2018; Sarkar et al., 2020; Portz and Lee, 2021), nuclear regulation (Kontopoulos et al., 2006; Pinho et al., 2019; Schaser et al., 2019; Vasquez et al., 2020), and proteostasis (Auluck et al., 2002; Colla et al., 2012; Yan et al., 2019; Karim et al., 2020; Sarkar et al., 2021) in neurotoxicity. Interestingly, spectrin has been implicated in the control of each of these cellular functions as well. Spectrin was originally identified as a key component of the subplasmalemmal cytoskeleton of the red blood cell critical to maintaining cell shape and integrity during mechanical deformation (Liem, 2016). Much subsequent investigation has focused on conceptually similar subplasmalemmal roles in a variety of cell types, particularly those, like cardiomyocytes, subject to mechanical stress. However, spectrin has also been localized to a variety of intracellular compartments, including transport vesicles, mitochondria, and the nucleus (Zagon et al., 1986), where the protein complex has been implicated in vesicle transport and DNA damage repair, among other functions (Lambert, 2018, 2019; Goodman et al., 2019; Morrow and Stankewich, 2021).

derived neurons shows an association between α -synuclein and β II-spectrin. The blot is reprobed with an antibody to GAPDH to illustrate equivalent protein levels. **D**, **E**, Immunofluorescence microscopy reveals subplasmalemmal staining pattern for ankyrin-B (red) in MAP2-positive (green) control neurons and increased cytoplasmic staining in patient neurons (arrows). **F**, **G**, Immunostaining for Na⁺/K⁺ ATPase (red) shows a plasma membrane staining pattern in MAP2-positive (green) control neurons increased cytoplasmic staining in α -synuclein triplication patient neurons (arrows). **H**, Loss of plasma membrane polarization as monitored by DiBAC₄(3) in α -synuclein triplication patient neurons compared with controls. **B**, **E**, **G**, **H**, Data are mean \pm SEM. *p* values determined with two-tailed *t* test. *I*-*L*, Immunostaining for ankyrin-G (*I*) or β IV-spectrin (*J*) identifies intact axon initial segments in most MAP2-positive control neurons (arrows) and increased numbers of neurons with loss or fragmentation of the axon initial segment (arrowheads) in α -synuclein triplication patient neurons, as quantified in **K**, **L**. Assays were performed at 21 DIV. Scale bars, 25 µm. Data are mean \pm SEM. *p* values determined with two-way ANOVA with Bonferroni *post hoc* test.

Thus, binding of α -synuclein to spectrin at multiple intracellular sites may perturb a number of key cell biological roles subserved by spectrin. Alternatively, we have previously described altered actin dynamics downstream of spectrin in α -synucleinopathy models, which controls mitochondrial dynamics and function. Some or all of the effects of α -synuclein may thus reflect altered organization and dynamics of the actin cytoskeleton following loss of β -spectrin binding to ankyrin and disruption of the subplasmalemmal spectrin network. Additional work will be needed to distinguish these possibilities.

In addition to the more general functions of spectrin in cellular biology, in neurons distinct spectrin isoforms organize and maintain specific subcellular domains, including the axonal initial segment and nodes of Ranvier, which are needed for initiation and propagation of action potentials (Teliska and Rasband, 2021). We show here that the axon initial segment is abnormal in neurons from patients with Parkinson's disease because of triplication of the α -synuclein locus compared with isogenic control neurons (Fig. 6I,J). Spectrins also form a key component of the periodic rings of actin and spectrin known as membraneassociated periodic cytoskeleton present in axons (Xu et al., 2013) and dendrites (D'Este et al., 2015; Han et al., 2017). In mouse models, disruption of either the membrane-associated periodic cytoskeleton on loss of α II-spectrin (Huang et al., 2017) or nodes of Ranvier with genetic deletion of β I- and β IV-spectrin (Liu et al., 2020) leads to axonal degeneration. Alteration of specific neuronal structures and function by pathologic binding of α -synuclein to β -spectrin may therefore promote neurotoxicity in α -synucleinopathy.

As well as colocalizing with α -synuclein in Lewy bodies, β -spectrin has also been reported to interact with α -synuclein in mouse brain (McFarland et al., 2008) and cultured cortical neurons (Chung et al., 2017). These findings raise the possibility that binding of α -synuclein to β -spectrin may be relevant to the normal function of α -synuclein. Although the precise role that α -synuclein plays in nervous system function remains unclear, multiple studies have demonstrated modulation of neurotransmitter release by α -synuclein, consistent with the presynaptic localization of the protein (Runwal and Edwards, 2021). Spectrins and ankyrins are also present in the presynapse (Zagon et al., 1986; Pielage et al., 2008; Smith et al., 2014) and might transduce or modulate the synaptic activity of α -synuclein.

The precise form of α -synuclein that interacts with β -spectrin in vivo requires further definition. In vitro (McFarland et al., 2008) and in vivo (Ordonez et al., 2018) evidence suggests that serine 129 phosphorylation promotes the interaction of α -synuclein with spectrin. Phosphorylation might influence the interaction of α -synuclein with β -spectrin directly, or might work through indirect effects on α -synuclein aggregation (Fujiwara et al., 2002; Ghanem et al., 2022). We and others have implicated oligometic forms of α -synuclein in neurotoxicity, with evidence for a protective role for larger inclusions, perhaps as a sink for toxic smaller aggregates (Chen and Feany, 2005; Periquet et al., 2007; Chen et al., 2009; Olsen and Feany, 2021; Panicker et al., 2021). Our current observation that large inclusions increase in numbers when α -synuclein neurotoxicity is reduced by elevating β -spectrin levels (Fig. 5*I*,*J*) is consistent with these prior data.

We show here that levels of β -spectrin strongly influence the ability of human α -synuclein to show toxicity to dopaminergic and nondopaminergic neurons *in vivo*. In particular, we find that increasing β -spectrin can protect from α -synuclein neurotoxicity by restoring the normal organization of the subplasmalemmal spectrin network and maintaining normal localization and activity of Na⁺/K⁺ ATPase (Figs. 1, 5). These results suggest that therapeutic strategies aimed at stabilization of the spectrin cytoskeleton (Morrow and Stankewich, 2021) or normalization of the activity of downstream targets represent potential new approaches to the treatment of Parkinson's disease and related α -synucleinopathies.

References

- Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a *Drosophila* model for Parkinson's disease. Science 295:865–868.
- Bhavsar MB, Cato G, Hauschild A, Leppik L, Costa Oliveira KM, Eischen-Loges MJ, Barker JH (2019) Membrane potential (Vmem) measurements during mesenchymal stem cell (MSC) proliferation and osteogenic differentiation. PeerJ 7:e6341.
- Book A, Guella I, Candido T, Brice A, Hattori N, Jeon B, Farrer MJ, SNCA Multiplication Investigators of the GEoPD Consortium (2018) A metaanalysis of α-synuclein multiplication in familial parkinsonism. Front Neurol 9:1021.
- Burré J, Sharma M, Südhof TC (2018) Cell biology and pathophysiology of α -synuclein. Cold Spring Harb Perspect Med 8:a02401.
- Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a *Drosophila* model of Parkinson disease. Nat Neurosci 8:657–663.
- Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119:3257–3265.
- Chung CY, et al. (2013) Identification and rescue of α -synuclein toxicity in Parkinson patient-derived neurons. Science 342:983–987.
- Chung CY, Khurana V, Yi S, Sahni N, Loh KH, Auluck PK, Baru V, Udeshi ND, Freyzon Y, Carr SA, Hill DE, Vidal M, Ting AY, Lindquist S (2017) In situ peroxidase labeling and mass-spectrometry connects alpha-synuclein directly to endocytic trafficking and mRNA metabolism in neurons. Cell Syst 4:242–250.e4.
- Clausen MV, Hilbers F, Poulsen H (2017) The structure and function of the Na,K-ATPase isoforms in health and disease. Front Physiol 8:371.
- Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL, Lee MK (2012) Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy *in vivo*. J Neurosci 32:3306–3320.
- Cousin MA, et al. (2021) Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome. Nat Genet 53:1006– 1021.
- Das A, Base C, Dhulipala S, Dubreuil RR (2006) Spectrin functions upstream of ankyrin in a spectrin cytoskeleton assembly pathway. J Cell Biol 175:325–335.
- Das A, Base C, Manna D, Cho W, Dubreuil RR (2008) Unexpected complexity in the mechanisms that target assembly of the spectrin cytoskeleton. J Biol Chem 283:12643–12653.
- de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525–535.
- D'Este E, Kamin D, Göttfert F, El-Hady A, Hell SW (2015) STED nanoscopy reveals the ubiquity of subcortical cytoskeleton periodicity in living neurons. Cell Rep 10:1246–1251.
- Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T (2011) Parkinson's disease induced pluripotent stem cells with triplication of the α -synuclein locus. Nat Commun 2:440.
- Dubreuil RR (2006) Functional links between membrane transport and the spectrin cytoskeleton. J Membr Biol 211:151–161.
- Dubreuil RR, Wang P, Dahl S, Lee J, Goldstein LS (2000) Drosophila beta spectrin functions independently of alpha spectrin to polarize the Na,K ATPase in epithelial cells. J Cell Biol 149:647–656.
- Feany MB, Bender WW (2000) A *Drosophila* model of Parkinson's disease. Nature 404:394–398.

- Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164.
- Galiano MR, Jha S, Ho TS, Zhang C, Ogawa Y, Chang KJ, Stankewich MC, Mohler PJ, Rasband MN (2012) A distal axonal cytoskeleton forms an intra-axonal boundary that controls axon initial segment assembly. Cell 149:1125–1139.
- Ghanem SS, et al. (2022) α -Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci USA 119:e2109617119.
- Goodman SR, Johnson D, Youngentob SL, Kakhniashvili D (2019) The Spectrinome: the interactome of a scaffold protein creating nuclear and cytoplasmic connectivity and function. Exp Biol Med (Maywood) 244:1273–1302.
- Han B, Zhou R, Xia C, Zhuang X (2017) Structural organization of the actinspectrin-based membrane skeleton in dendrites and soma of neurons. Proc Natl Acad Sci USA 114:E6678–E6685.
- Ho GP, Ramalingam N, Imberdis T, Wilkie EC, Dettmer U, Selkoe DJ (2021) Upregulation of cellular palmitoylation mitigates α-synuclein accumulation and neurotoxicity. Mov Disord 36:348–359.
- Huang CY, Zhang C, Zollinger DR, Leterrier C, Rasband MN (2017) An α II spectrin-based cytoskeleton protects large-diameter myelinated axons from degeneration. J Neurosci 37:11323–11334.
- Karim MR, Liao EE, Kim J, Meints J, Martinez HM, Pletnikova O, Troncoso JC, Lee MK (2020) α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener 15:27.
- Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22:2780–2791.
- Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 100:2884–2889.
- Kontopoulos E, Parvin JD, Feany MB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012–3023.
- Kordeli E, Bennett V (1991) Distinct ankyrin isoforms at neuron cell bodies and nodes of Ranvier resolved using erythrocyte ankyrin-deficient mice. J Cell Biol 114:1243–1259.
- Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106–108.
- Kuwahara T, Tonegawa R, Ito G, Mitani S, Iwatsubo T (2012) Phosphorylation of α -synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in *Caenorhabditis elegans*. J Biol Chem 287:7098–7109.
- Lakso M, Vartiainen S, Moilanen AM, Sirviö J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in *Caenorhabditis elegans* overexpressing human alpha-synuclein. J Neurochem 86:165–172.
- Lambert MW (2018) Spectrin and its interacting partners in nuclear structure and function. Exp Biol Med (Maywood) 243:507–524.
- Lambert MW (2019) The functional importance of lamins, actin, myosin, spectrin and the LINC complex in DNA repair. Exp Biol Med (Maywood) 244:1382–1406.
- Lee HJ, Lee K, Im H (2012) α-Synuclein modulates neurite outgrowth by interacting with SPTBN1. Biochem Biophys Res Commun 424:497–502.
- Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neuro-degenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99:8968–8973.
- Leterrier C (2018) The axon initial segment: an updated viewpoint. J Neurosci 38:2135–2145.
- Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J (2007) Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol 17:139–145.
- Liem RK (2016) Cytoskeletal integrators: the spectrin superfamily. Cold Spring Harb Perspect Biol 8:a018259.

- Liu CH, Stevens SR, Teliska LH, Stankewich M, Mohler PJ, Hund TJ, Rasband MN (2020) Nodal β spectrins are required to maintain Na⁺ channel clustering and axon integrity. Elife 9:e52378.
- Lo Bianco C, Shorter J, Régulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118:3087–3097.
- Lorenzo DN (2020) Cargo hold and delivery: ankyrins, spectrins, and their functional patterning of neurons. Cytoskeleton (Hoboken) 77:129–148.
- Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK (2006) Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26:41–50.
- Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–1269.
- Mazock GH, Das A, Base C, Dubreuil RR (2010) Transgene rescue identifies an essential function for *Drosophila* beta spectrin in the nervous system and a selective requirement for ankyrin-2-binding activity. Mol Biol Cell 21:2860–2868.
- McFarland MA, Ellis CE, Markey SP, Nussbaum RL (2008) Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics 7:2123–2137.
- Morrow JS, Stankewich MC (2021) The spread of spectrin in ataxia and neurodegenerative disease. J Exp Neurol 2:131–139.
- O'Donnell KC, Lulla A, Stahl MC, Wheat ND, Bronstein JM, Sagasti A (2014) Axon degeneration and PGC-1 α -mediated protection in a zebrafish model of α -synuclein toxicity. Dis Model Mech 7:571–582.
- Olsen AL, Feany MB (2021) Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity. Neurobiol Dis 159:105482.
- Ordonez DG, Lee MK, Feany MB (2018) α -Synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron 97:108–124.e6.
- Panicker N, Ge P, Dawson VL, Dawson TM (2021) The cell biology of Parkinson's disease. J Cell Biol 220:e202012095.
- Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity *in vivo*. J Neurosci 27:3338–3346.
- Peuralinna T, Myllykangas L, Oinas M, Nalls MA, Keage HA, Isoviita VM, Valori M, Polvikoski T, Paetau A, Sulkava R, Ince PG, Zaccai J, Brayne C, Traynor BJ, Hardy J, Singleton AB, Tienari PJ (2015) Genome-wide association study of neocortical Lewy-related pathology. Ann Clin Transl Neurol 2:920–931.
- Pielage J, Cheng L, Fetter RD, Carlton PM, Sedat JW, Davis GW (2008) A presynaptic giant ankyrin stabilizes the NMJ through regulation of presynaptic microtubules and transsynaptic cell adhesion. Neuron 58:195– 209.
- Pinho R, et al. (2019) Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Hum Mol Genet 28:31–50.
- Polymeropoulos MH, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045–2047.
- Portz P, Lee MK (2021) Changes in Drp1 function and mitochondrial morphology are associated with the α -synuclein pathology in a transgenic mouse model of Parkinson's disease. Cells 10:885.
- Runwal G, Edwards RH (2021) The membrane interactions of synuclein: physiology and pathology. Annu Rev Pathol 16:465–485.
- Sarkar S, Murphy MA, Dammer EB, Olsen AL, Rangaraju S, Fraenkel E, Feany MB (2020) Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy. NPJ Parkinsons Dis 6:40.
- Sarkar S, Olsen AL, Sygnecka K, Lohr KM, Feany MB (2021) α -Synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genet 17:e1009359.
- Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW, Weston LJ, Owen N, Weissman TA, Luna E, Raber J, Luk KC, McCullough AK, Woltjer RL, Unni VK (2019) Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Sci Rep 9:10919.
- Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222.
- Smith KR, Kopeikina KJ, Fawcett-Patel JM, Leaderbrand K, Gao R, Schürmann B, Myczek K, Radulovic J, Swanson GT, Penzes P (2014)

Psychiatric risk factor ANK3/ankyrin-G nanodomains regulate the structure and function of glutamatergic synapses. Neuron 84:399–415.

Sun B, Salvaterra PM (1995) Characterization of nervana, a Drosophila melanogaster neuron-specific glycoprotein antigen recognized by anti-horseradish peroxidase antibodies. J Neurochem 65:434–443.

Teliska LH, Rasband MN (2021) Spectrins. Curr Biol 31:R504-R506.

- Torii T, Ogawa Y, Liu CH, Ho TS, Hamdan H, Wang CC, Oses-Prieto JA, Burlingame AL, Rasband MN (2020) NuMA1 promotes axon initial segment assembly through inhibition of endocytosis. J Cell Biol 219: e201907048.
- Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015–1022.
- Vasquez V, Mitra J, Wang H, Hegde PM, Rao KS, Hegde ML (2020) A multifaceted genotoxic network of alpha-synuclein in the nucleus and mitochondria of dopaminergic neurons in Parkinson's disease: emerging concepts and challenges. Prog Neurobiol 185:101729.
- Vidyadhara DJ, Lee JE, Chandra SS (2019) Role of the endolysosomal system in Parkinson's disease. J Neurochem 150:487–506.

- Weiß I, Bohrmann J (2019) Electrochemical gradients are involved in regulating cytoskeletal patterns during epithelial morphogenesis in the *Drosophila* ovary. BMC Dev Biol 19:22.
- Xu K, Zhong G, Zhuang X (2013) Actin, spectrin, and associated proteins form a periodic cytoskeletal structure in axons. Science 339:452–456.
- Yan C, Liu J, Gao J, Sun Y, Zhang L, Song H, Xue L, Zhan L, Gao G, Ke Z, Liu Y, Liu J (2019) IRE1 promotes neurodegeneration through autophagy-dependent neuron death in the *Drosophila* model of Parkinson's disease. Cell Death Dis 10:800.
- Yang G, Schmiel L, Zhou M, Cintina I, Spencer D, Hogan P (2019) The economic burden of Parkinson's disease. NPJ Parkinson's disease 6:1–9.
- Zagon IS, Higbee R, Riederer BM, Goodman SR (1986) Spectrin subtypes in mammalian brain: an immunoelectron microscopic study. J Neurosci 6:2977–2986.
- Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164–173.